AbbVie Inc. (NYSE:ABBV), which has been in the news thanks to the recent approval of its hepatitis C virus (HCV) treatment Viekira Pak, will be reporting fourth quarter and full year 2014 results on Jan 30, before the market opens. On Thursday shares of AbbVie Inc. (NYSE:ABBV) closed at $63.12. Company’s EPS growth for next 5 years is recorded as 15.40%.
On January 15, Asanko Gold Inc. (NYSEMKT:AKG) announced a construction update on its Ghana-based Asanko gold mine. The first phase will produce 190,000 ounces of gold a year, and first gold pour is set for Q1 2016. Phase 1 construction 24% complete and on schedule for first gold in Q1 2016; Project spend on budget with US$170 million of the US$295 million capital cost committed; Mining contractor mobilized to site and pre-stripping of the main Nkran pit underway. Asanko Gold Inc. (NYSEMKT:AKG) in last trading activity moved down -3.75% to close at $1.54. Company weekly performance is -7.23% while its quarterly performance stands at -8.33%. Asanko Gold Inc. (NYSEMKT:AKG) is -44.40% away from its 52 week high.
On January 17, Mechel OAO (NYSE:MTL) reported extending the maturity of its credit lines from Credit Bank of Moscow totaling USD 105 million. Mechel Group’s enterprise — Mechel Service OOO — signed an agreement with Credit Bank of Moscow for extending the maturity of our existing credit lines totaling USD 105 million until February 2016. The security pledge and interest rate remain unchanged. On last trading day Mechel OAO (NYSE:MTL) moved up 30.34% to close at $1.16. Its volatility for the week is 11.84% while volatility for the month is 10.76%. MTL’s sales growth for past 5 years was -2.90% and its EPS growth for past 5 years was -27.50%. Mechel OAO (NYSE:MTL) monthly performance is 70.59%.
On January 27, TransCelerate BioPharma Inc. announced two new members, Merck & Co. Inc. (NYSE:MRK), and Novo Nordisk, to the biopharmaceutical non-profit organization. In addition, TransCelerate has appointed Briggs Morrison, MD, Executive Vice President, Global Medicines Development at AstraZeneca, to the position of Chair of the Board of Directors.On Thursday shares of Merck & Co. Inc. (NYSE:MRK) closed at $62.09. Company’s sales growth for last 5 years was 13.00% and EPS growth for next 5 years is recorded as 5.86%.
Micrel, Inc. (NASDAQ:MCRL) reported Q4 EPS of $0.08, $0.04 better than the analyst estimate of $0.04. Revenue for the quarter came in at $57.9 million versus the consensus estimate of $59.55 million. Micrel, Inc. sees Q1 2015 EPS of $0.04-$0.07, versus the consensus of $0.06. On last trading day Micrel Inc. (NASDAQ:MCRL) moved up 0.63% to close at $14.28. Its volatility for the week is 2.42% while volatility for the month is 3.04%. MCRL’s sales growth for past 5 years was -1.80% and its EPS growth for past 5 years was -5.60%. Micrel Inc. (NASDAQ:MCRL) monthly performance is -1.18%.